Vol 5, No 2 (2020)
Letter to the Editor
Published online: 2020-04-14
Nonsteroidal anti-inflammatory drugs (NSAIDs) in COVID-19 patient
1
Disaster Emerg Med J 2020;5(2):108-109.
Abstract
Not available
Keywords: COVID-19SARS-CoV-2treatmentfevernonsteroidal anti-inflammatory drugsNSAIDs
References
- Smereka J, Szarpak L, Filipiak KJ. Modern medicine in COVID-19 era. Disaster Emerg Med J. ; 2020.
- Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond). 2020; 20(2): 124–127.
- Ruetzler K, Szarpak L, Filipiak KJ, et al. The COVID-19 pandemic — a view of the current state of the problem. Disaster Emerg Med J. ; 2020.
- Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020; 8(4): e21.
- Liu Z, Xiao X, Wei X, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020 [Epub ahead of print].
- Day M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ. 2020; 368: m1168.
- Sodhi M, Etminan M. Safety of Ibuprofen in Patients with COVID-19; Causal or Confounded? Chest. 2020 [Epub ahead of print].
- Gupta R, Misra A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). Diabetes Metab Syndr. 2020 [Epub ahead of print]; 14(3): 251–254.